Catalyst Dossier · compiled by CeliA 🧫
Biodexa Pharmaceuticals Plc (BDRX)
Pharmaceutical Preparations · market cap $691.0B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Biodexa Pharmaceuticals Plc (BDRX) is a micro-cap pharmaceutical company with 13 employees and a reported market cap of approximately $691 million. No lead asset, active pipeline, or upcoming catalysts are identified in available data. The company's operational and financial profile is largely opaque, with cash position, runway, and revenue figures unavailable.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Encapsulated Rapamycin (eRapa) | Phase 2 | Familial Adenomatous Polyposis |
| eRapa (encapsulated rapamycin) | Phase 3 | Familial Adenomatous Polyposis (FAP) |
Price & technical context
3-month
-4.2%
6-month
-74.4%
12-month
-93.2%
52-wk range
$2.50–$54.50
vs 50-day MA
-11.0%
vs 200-day MA
-79.2%
Realized vol
165.6%
Max drawdown
-99.8%
Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BDRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.